Aarti Drugs Limited announced its financial results for the quarter ended September 30, 2025 (Q2 FY26), posting a solid year-on-year rise in both revenue and profit, supported by strong operational performance.
The company’s revenue from operations stood at Rs 652.79 crore, up 9% YoY from Rs 598.33 crore reported in the same quarter last year. Total income came in at Rs 652.88 crore, compared to Rs 599.81 crore in Q2 FY25.
On the profitability front, net profit rose 29.2% YoY to Rs 45.2 crore in Q2 FY26, against Rs 35 crore in Q2 FY25. Sequentially, the profit increased 8% from Rs 39.1 crore in Q1 FY26.
Aarti Drugs reported an improvement in operating performance for the quarter ended September 2026, with EBITDA rising to Rs 75.2 crore from Rs 59.5 crore in the same period last year. The company’s EBITDA margin also expanded to 13% from 11% year-on-year, reflecting better cost management and operational efficiency during the quarter.
For the half year ended September 2025, total income was Rs 1,243.7 crore, a 7.7% rise from Rs 1,156.3 crore in the previous year. Net profit for H1 FY26 stood at Rs 91.9 crore, up from Rs 68.2 crore last year.
The company attributed the improved earnings to better capacity utilization and product mix optimization across its active pharmaceutical ingredient (API) and formulation segments.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
